Novel Sars-Cov-2 Pandemic Transmission With Ongoing Antiviral Therapies And Vaccine Design

• Published in: Postępy mikrobiologii Vol. 60; no. 1; pp. 13 - 20
• Main Authors: Yameen, Muhammad, Sattar, Sara, Khalid, Ayesha, Aslam, Muhammad Aamir, Zafar, Nishat, Saeed, Muhammad Hassan, Arif, Muhammad Haseeb, Jahangeer, Muhammad, Qadeer, Azka, Hussain, Shoukat, Aamir, Muhammad, Mukhtar, Sania, Nasir, Huma, Shahzad, Asif
• Format: Journal Article
• Language: English
• Published: Exeley Inc 01.03.2021; Sciendo
• Subjects: BCG; BCG vaccines; Biological diversity; China; Coronaviruses; covid-19; Earthquakes; Epidemics; Genomes; Genomics; Health aspects; Pakistan; sars-cov-2; Vaccination; Vaccines; viral genome; who; China; Pakistan
• ISSN: 2545-3149; 0079-4252; 2545-3149
• DOI: 10.21307/PM-2021.60.1.02

Abstract Starting from the end of 2019 the new SARs-CoV-2 virus, in the period of a few months, had spread to 210 countries and its territories. The Wuhan wild animal market, in Hubei province, China is considered the epicenter of this pandemic. WHO declared the name COVID-19 to designate the disease caused by the SARS-CoV-2 virus. It is the third coronavirus pandemic after SARS in 2002–2003 and MERS-CoV in 2012. Genome sequencing of this new COVID-19/SARS-CoV-2 virus shows slight genetic diversity when compared to other coronaviruses. Owing to its pathogenesis, and less known replication cycle, no universal antiviral treatment can be applied and vaccine preparation is still a larger challenge. The present article will highlight transmission, pandemic status, genetic diversity current antiviral therapy, and vaccine trials for COVID-19. 1. Introduction. 2. Pathogenesis of coronaviruses. 3. Genetic diversity. 4. Transmission. 5. Vaccination strategies against COVID-19. 6. In Process Vaccination strategies against COVID-19. 7. Lack of antiviral treatment and antiviral treatment studies. 8. Precautions. 9. Conclusions